M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza

Yasuko Hatta1, David Boltz2, Sally Sarawar3

  • 1FluGen Inc., Madison, WI 53711, USA.

Vaccine
|July 3, 2017
PubMed

Insights

A novel M2-deficient single replication (M2SR) influenza vaccine demonstrated significant protection against highly pathogenic avian influenza H5N1 in mice and ferrets. Both homologous M2SR H5N1 and heterologous M2SR H1N1 vaccines offered cross-protection, highlighting the M2SR platform's versatility for universal influenza vaccines.

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Highly pathogenic avian influenza H5N1 poses a significant pandemic threat.
  • Existing influenza vaccines require frequent updates due to viral evolution.
  • A universal influenza vaccine is needed for broad and durable protection.

Purpose of the Study:

  • To evaluate the efficacy of a novel M2-deficient single replication (M2SR) influenza vaccine against H5N1 influenza.
  • To assess the protective capabilities of M2SR H5N1 and M2SR H1N1 vaccines in mouse and ferret models.
  • To investigate the immune responses induced by M2SR vaccines against H5N1 influenza.

Main Methods:

  • Mice and ferrets were vaccinated with M2SR viruses encoding H5N1 or H1N1 hemagglutinin and neuraminidase.
  • Vaccinated animals were challenged with a lethal dose of H5N1 influenza virus.
  • Humoral immune responses, including hemagglutination inhibition (HAI) titers and antibody classes (IgG, IgA), were measured.

Main Results:

  • M2SR H5N1 vaccination conferred sterile immunity and 100% survival in mice challenged with H5N1, outperforming recombinant H5 HA vaccines.
  • M2SR H1N1 also provided protection in mice and ferrets against H5N1 challenge, demonstrating cross-protective immunity without high HAI titers.
  • Both M2SR H5N1 and M2SR H1N1 vaccines protected ferrets against lethal H5N1 challenge, with prime-boost regimens offering optimal protection.

Conclusions:

  • The M2SR influenza vaccine platform effectively protects against highly pathogenic H5N1 influenza.
  • Both homologous M2SR H5N1 and heterologous M2SR H1N1 vaccines exhibit cross-protective attributes.
  • The M2SR platform shows promise for developing a universal influenza vaccine with broad efficacy.